Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study.
DAPSA
apremilast
psoriatic arthritis
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
02 Feb 2023
02 Feb 2023
Historique:
received:
31
12
2022
revised:
29
01
2023
accepted:
31
01
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to analyze the predictors of clinical response. All PsA consecutive patients treated with apremilast in fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline, 6 months, and 12 months were recorded. The Mann-Whitney test and chi-squared tests assessed the differences between independent groups, whereas the Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. Logistic regressions verified if there were factors associated with achievement of DAPSA low disease activity or remission at 6 and 12 months. DAPSA low disease activity or remission rates at 6 and 12 months were observed, respectively, in 42.7% ( Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA.
Sections du résumé
BACKGROUND
BACKGROUND
To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to analyze the predictors of clinical response.
METHODS
METHODS
All PsA consecutive patients treated with apremilast in fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline, 6 months, and 12 months were recorded. The Mann-Whitney test and chi-squared tests assessed the differences between independent groups, whereas the Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. Logistic regressions verified if there were factors associated with achievement of DAPSA low disease activity or remission at 6 and 12 months.
RESULTS
RESULTS
DAPSA low disease activity or remission rates at 6 and 12 months were observed, respectively, in 42.7% (
CONCLUSIONS
CONCLUSIONS
Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA.
Identifiants
pubmed: 36830969
pii: biomedicines11020433
doi: 10.3390/biomedicines11020433
pmc: PMC9953385
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Med (Lond). 2017 Feb;17(1):65-70
pubmed: 28148584
Ann Rheum Dis. 2004 Nov;63 Suppl 2:ii13-ii17
pubmed: 15479864
Clin Rheumatol. 2022 Oct;41(10):3219-3225
pubmed: 35796847
Ann Rheum Dis. 2010 Aug;69(8):1441-7
pubmed: 20525844
Clin Exp Rheumatol. 2020 Jan-Feb;38(1):19-26
pubmed: 31074721
J Rheumatol. 2021 May;48(5):693-697
pubmed: 33191289
Ann Rheum Dis. 2016 Mar;75(3):499-510
pubmed: 26644232
Clin Rheumatol. 2019 Nov;38(11):3145-3151
pubmed: 31317423
Rheumatology (Oxford). 2018 Jul 1;57(7):1253-1263
pubmed: 29635379
J Rheumatol. 2016 Sep;43(9):1724-34
pubmed: 27422893
Adv Ther. 2022 Feb;39(2):1055-1067
pubmed: 34977986
Rheumatology (Oxford). 2018 Mar 1;57(3):578-580
pubmed: 29272544
Ann Rheum Dis. 2016 Jun;75(6):1065-73
pubmed: 26792812
J Rheumatol. 2022 Jul;49(7):694-699
pubmed: 35428720
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
Ann Rheum Dis. 2014 Jun;73(6):1020-6
pubmed: 24595547
Arthritis Care Res (Hoboken). 2020 Jun;72(6):814-821
pubmed: 31909868